Androgen receptor co-regulation in prostate cancer

Abstract excerpt

Prostate cancer (PCa) progression relies on androgen receptor (AR) action. Preventing AR's ligand-activation is the frontline treatment for metastatic PCa. Androgen deprivation therapy (ADT) that inhibits AR ligand-binding initially induces remission but eventually fails, mainly because of adaptive PCa responses that restore AR action. The vast majority of castration-resistant PCa (CRPC) continues to rely on AR...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Estrogen and related hormone effects
• Share to Hormonal and reproductive studies
• Share to Prostate Cancer Treatment and Research